DrugDashboards

Caplyta

lumateperone · LUMATEPERONE 42 mg/1 · Capsule · Oral · Intra-Cellular Therapies, Inc

NDC 72060-0142-07 · 7 CAPSULE in 1 BOTTLE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 72060-0142-40) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$57.43per unit
middle half $56.76$59.25 · 5,496 plans · Apr 1, 2026
Est. net of rebates
$34.46–$43.07
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
100%of plans cover it
tier 5 · prior auth 29% · step therapy 5% · qty limit 95%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for lumateperone (oral solid) in the next 90 days

sole-source market · price up 5% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $1,686.17 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA209500
TE code
Approval date
Dec 20, 2019
Patents / exclusivity
60 patents, 6 exclusivities
TypeNumber / codeExpires
exclusivityM-319Apr 24, 2029
exclusivityM-319Apr 24, 2029
exclusivityM-319Apr 24, 2029
exclusivityI-904Nov 5, 2028
exclusivityI-904Nov 5, 2028
exclusivityI-904Nov 5, 2028
patent11753419Dec 10, 2040
patent12122792Dec 10, 2040
patent12122792Dec 10, 2040
patent12122792Dec 10, 2040
patent11753419Dec 10, 2040
patent12410195Dec 10, 2040

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of lumateperone (Capsule)

LabelerStrengthFirst seenLast seen
Intra-Cellular Therapies, IncLUMATEPERONE 10.5 mg/1Jul 15, 2026Sep 2, 2026
Intra-Cellular Therapies, IncLUMATEPERONE 21 mg/1Jul 15, 2026Sep 2, 2026
Intra-Cellular Therapies, IncLUMATEPERONE 42 mg/1Jul 15, 2026Sep 2, 2026
Patheon Inc.LUMATEPERONE 42 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Caplyta — NDC 72060-0142-07," retrieved September 3, 2026, https://drugdashboards.com/drug/72060014207.

Free to cite with attribution — see how the data is put together.